James Hardie sales jump 64% in Q1 FY27 as management lifts full-year outlook
AI Market Summary
James Hardie's FY27 Q1 results showed strong momentum: reported sales +64% and adjusted EBITDA +79%, with pro forma sales still up 12% including AZEK. Management raised FY27 pro forma EBITDA growth guidance to 7.4%–13.7%. Improved free cash flow, planned Fermacell sale proceeds earmarked for debt reduction, and a US$250m buyback support balance-sheet confidence, reinforcing positive Australia industrials sentiment.
Impact level
● Low
Affected assets
NCSKASX2USD/USDT-0.54%
AI Insight · NCSKASX2USD/USDTAI Insight
▲ Bullish
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
James Hardie Industries reported a 64% year-on-year increase in first-quarter FY27 sales to US$1.47 billion, while adjusted EBITDA rose 79% to US$422 million. Management also upgraded its full-year guidance, forecasting proforma adjusted EBITDA growth of 7.4% to 13.7%. Morgan Stanley expects the company’s earnings in 2029 could be about 19% above current market expectations.
